Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05411744 · ClinicalTrials.gov registry record · Phase 4
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
A Phase 4 study of End Stage Renal Disease and Latent Tuberculosis, sponsored by Rutgers, The State University of New Jersey.
- Active
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05411744 is a Phase 4 study of End Stage Renal Disease and Latent Tuberculosis that is active but no longer recruiting, run by Rutgers, The State University of New Jersey. The registered enrollment target is 25 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05411744, a Phase 4 study of End Stage Renal Disease and Latent Tuberculosis, is active but no longer recruiting, sponsored by Rutgers, The State University of New Jersey.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, single-center, single-arm, open-label study investigating the safety, compliance and pharmacokinetics of 1-month treatment of Isoniazid, Rifapentine and Vitamin B6 in renal transplant candidates.
Conditions Studied
Interventions
- DRUG 1 month Rifapentine, Isoniazid and Vitamin B6
Study Locations (1)
New Jersey
- Pinki J Bhatt - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05411744
The ClinicalTrials.gov registry entry for NCT05411744 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (97% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which 1 month Rifapentine, Isoniazid and Vitamin B6 is the first listed.
NCT05411744 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05411744 about?
NCT05411744 is a clinical study titled "One-month Latent Tuberculosis Treatment for Renal Transplant Candidates". This is a prospective, single-center, single-arm, open-label study investigating the safety, compliance and pharmacokinetics of 1-month treatment of Isoniazid, Rifapentine and Vitamin B6 in renal transplant candidates.
What is the current status of trial NCT05411744?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2022-07-01. Estimated completion is 2029-06-30.
What conditions does trial NCT05411744 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Latent Tuberculosis, Renal Transplant Candidate for Right Kidney, Renal Transplant Candidate for Left Kidney.
What interventions are being tested in trial NCT05411744?
The interventions under investigation include: 1 month Rifapentine, Isoniazid and Vitamin B6 (DRUG).
Who is sponsoring clinical trial NCT05411744?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05411744 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ferric Citrate in ESRD Pilot Project
ACTIVE NOT RECRUITING · Phase 4
-
Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients
COMPLETED · Phase 4
-
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
COMPLETED · Phase 4
-
Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis
COMPLETED · Phase 4
-
Triferic AVNU Infusion Via Freedom Pump During Hemodialysis
COMPLETED · Phase 4
-
Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.